| TOP STORY | A “Passport” for the Immune System The authors developed a “passport” that could be attached to therapeutic particles and devices, tricking macrophages into leaving them alone. They simulated and synthesized the simplest functional version of a membrane protein, and then stuck this ‘minimal peptide’ on the exterior of some plastic nanoparticles. [Press release from the University of Pennsylvania discussing online prepublication in Science] Press Release | Abstract | Video |
| PUBLICATIONS (Ranked by impact factor of the journal) | Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA Researchers found that mammalian cytosolic extracts synthesized cyclic guanosine monophosphate-adenosine monophosphate (cyclic GMP-AMP, or cGAMP) in vitro from adenosine triphosphate and guanosine triphosphate in the presence of DNA but not RNA. DNA transfection or DNA virus infection of mammalian cells also triggered cGAMP production. cGAMP bound to STING, leading to the activation of IRF3 and induction of interferon-β. [Science] Abstract | Press Release Depletion of FOXP3+ Regulatory T Cells Promotes Hypercholesterolemia and Atherosclerosis To define the role of FOXP3-expressing regulatory T cells (Tregs) in atherosclerosis, the authors used the DEREG mouse, which expresses the diphtheria toxin receptor under control of the Treg-specific Foxp3 promoter, allowing for specific ablation of FOXP3+ Tregs. [J Clin Invest] Full Article Essential Requirement for IRF8 and SLC15A4 Implicates Plasmacytoid Dendritic Cells in the Pathogenesis of Lupus In vitro evidence suggests that plasmacytoid dendritic cells are intimately involved in the pathogenesis of lupus. However, it remains to be determined whether these cells are required in vivo for disease development, and whether their contribution is restricted to hyperproduction of type I IFNs. To address this, researchers created lupus-predisposed mice lacking the IFN regulatory factor 8 (IRF8) or carrying a mutation that impairs the peptide/histidine transporter solute carrier family 15, member 4 (SLC15A4). [Proc Natl Acad Sci USA] Abstract Interleukin-7 Facilitates HIV-1 Transmission to Cervico-Vaginal Tissue Ex Vivo Scientists found that interleukin (IL)-7 significantly enhanced virus replication in ex vivo infected cervico-vaginal tissue. Similarly, they observed an enhancement of HIV-1 replication in lymphoid tissue explants. Analysis of T cells isolated from infected tissues showed that IL-7 reduced CD4+ T cell depletion preventing apoptosis, as shown by the decrease in the number of cells expressing the apoptotic marker APO2.7 and the increase in the expression of the anti-apoptotic protein B-cell lymphoma-2. [PLoS Pathog] Abstract | Press Release Mucosal Imprinting of Vaccine-Induced CD8+ T Cells Is Crucial to Inhibit the Growth of Mucosal Tumors The authors identified a link between the route of vaccination and the induction of a mucosal homing program on induced CD8+ T cells that controlled their trafficking. [Sci Transl Med] Abstract IGF-1 Promotes the Development and Cytotoxic Activity of Human NK Cells Researchers identified an essential role for insulin-like growth factor 1 (IGF-1) in the positive regulation of human natural killer (NK) cell development and cytotoxicity. Specifically, they showed that human NK cells have the ability to produce IGF-1 and that differential endogenous IGF-1 expression leads to disparate cytotoxicity in human primary NK cells. [Nat Commun] Full Article The Level of p38α MAPK Activation in Airway Epithelial Cells Determines the Onset of Innate Immune Responses to Planktonic and Biofilm Pseudomonas aeruginosa Scientists report that in airway epithelial cells a threshold of p38α MAPK activation is required to trigger neutrophil recruitment, which is influenced by extrinsic and intrinsic factors. [J Infect Dis] Abstract Tumor-Specific T Cells in Human Merkel Cell Carcinomas: A Possible Role for Tregs and T Cell Exhaustion in Reducing T Cell Responses Merkel cell carcinomas (MCC) tumors were infiltrated by T cells, including effector, central memory and regulatory T cells (Tregs). Infiltrating T cells showed markedly reduced activation as evidenced by reduced expression of CD69 and CD25. Treatment of MCC tumors in vitro with IL-2 and IL-15 led to T cell activation, proliferation, enhanced cytokine production and loss of viable tumor cells from cultures. [J Invest Dermatol] Abstract Imatinib Ameliorates Neuroinflammation in a Rat Model of Multiple Sclerosis by Enhancing Blood-Brain Barrier Integrity and by Modulating the Peripheral Immune Response Researchers demonstrated that the small tyrosine kinase inhibitor imatinib enhances blood-brain barrier integrity in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. Treatment was accompanied by decreased central nervous system inflammation and demyelination and especially reduced T-cell recruitment. [PLoS One] Full Article | Press Release
|
| REVIEWS | Transcriptional Regulation of Follicular T-Helper (Tfh) Cells This review summarizes the recent progress in molecular mechanisms underlying Tfh differentiation and discusses the future perspectives for this important area of research. [Immunol Rev] Abstract The Life of Regulatory T Cells Antigen exposure and the presence of IL-2 are key determinants in the generation of memory Foxp3+ regulatory T (Treg) cells. These results provide a foundation for studying the role of memory Treg cells in controlling and treating autoimmune disorders and for testing the hypothesis that defects in the generation and maintenance of these cells underlie chronic, relapsing inflammatory diseases. [Ann NY Acad Sci] Abstract Negative Regulatory Approaches to the Attenuation of Toll-Like Receptor Signaling This review covers the modulation of toll-like receptor signaling at multiple levels, including adaptor complex destabilization, phosphorylation and ubiquitin-mediated degradation of signal proteins, manipulation of other receptors, and transcriptional regulation. Synthetic inhibitors are also briefly discussed to highlight negative regulatory approaches in the treatment of inflammatory diseases. [Exp Mol Med] Abstract |
| INDUSTRY NEWS | Xencor Initiates Phase Ib/IIa Trial of XmAbR5871 for Autoimmune Disease Xencor, Inc. announced that the first patient has been dosed in a Phase Ib/IIa clinical trial of XmAb®5871 in patients with moderate to severe rheumatoid arthritis. XmAb5871 is the first in a new class of therapeutic antibodies targeting the CD32b pathway in B cells, which shows potential to suppress autoimmune disorders without the side effects caused by B cell depletion. [Xencor, Inc.] Press Release Immune Initiates Bertilimumab Phase II Clinical Trial in Ulcerative Colitis Immune Pharmaceuticals Ltd. (Immune) and EpiCept announced that Immune is initiating a Phase II double-blind placebo controlled study with its lead drug, bertilimumab, in patients with moderate-to-severe ulcerative colitis. Bertilimumab is a first-in-class fully human monoclonal antibody targeting eotaxin-1, a chemokine small protein regulating eosinophilic inflammation. [Immune Pharmaceuticals Ltd.] Press Release Coronado Biosciences Signs Research Collaboration and License Agreement with Freie Universität Berlin for Secretory Products of Trichuris suis Coronado Biosciences, Inc. announced the signing of a sponsored research agreement and a joint ownership and exclusive license agreement with Freie Universität Berlin for the identification and evaluation of secretory proteins from Trichuris suis. The evaluation will be done in various pre-clinical in vitro and animal models which will further describe the mechanism of action for Trichuris suis ova and potentially lead to newly identified immune regulatory pharmaceutical agents. [Coronado Biosciences, Inc.] Press Release |
|
|
|